Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

The Lancet Infectious Diseases

Volumn 14, Issue 7, 2014, Pages 590-599

  Pozniak, Anton ^a   Markowitz, Martin ^b   Mills, Anthony ^c   Stellbrink, Hans Juergen ^d   Antela, Antonio ^e   Domingo, Pere ^f   Girard, Pierre Marie ^g   Henry, Keith ^h   Nguyen, Thai ⁱ   Piontkowsky, David ⁱ   Garner, Will ⁱ   White, Kirsten ⁱ   Guyer, Bill ⁱ  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c Anthony Mills MD Inc   (United States)

^d Infektionsmedizinisches Centrum Hamburg   (Germany)

^e University Hospital of Santiago de Compostela   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HÔPITAL SAINT ANTOINE   (France)

^h HENNEPIN COUNTY MEDICAL CENTER   (United States)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; CREATININE; EFAVIRENZ; ELVITEGRAVIR; EMTRICITABINE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR; VIRUS RNA; ETRAVIRINE; NEVIRAPINE; RILPIVIRINE;

ABNORMAL LABORATORY RESULT; ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIVID DREAM; ANXIETY; CHOLESTEROL BLOOD LEVEL; DIZZINESS; DRUG SUBSTITUTION; DYSGEUSIA; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; MOOD CHANGE; MUSCLE ATROPHY; PARESTHESIA; PROTEINURIA; PRURIGO; SUICIDE;

ADENINE; ADULT; ANTI-HIV AGENTS; CARBAMATES; DEOXYCYTIDINE; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; QUINOLONES; REVERSE TRANSCRIPTASE INHIBITORS; THIAZOLES; VIRAL LOAD;

EID: 84904266222     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70796-0     Document Type: Article

References (30)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Panel on antiretroviral guidelines for adults and adolescents, (accessed May 22, 2014). http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
2. EACS guidelines version 7.0 European AIDS Clinical Society, (accessed March 25, 2014). http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf.
3. SUSTIVA (efavirenz) capsules and tablets for oral use. US prescribing information Bristol-Myers Squibb, (accessed May 22, 2014). http://packageinserts.bms.com/pi/pi_sustiva.pdf.
4. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012, 379:2439-2448.
5. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012, 379:2429-2438.
6. Wohl D, Cohen C, Gallant JE, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir df (stb) demonstrates durable efficacy and favorable long-term safety profile versus efavirenz/emtricitabine/tenofovir df (atr) at week 144 in treatment-naive hiv patients. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO, USA; Sept 10-13, 2013. H-672A.
7. Clumeck N, Molina JM, Henry K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir df (stb) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir df in treatment-naïve HIV-1 infected patients: week 144 results. 14th European AIDS Conference; Brussels, Belgium; Oct 16-19, 2013. abstract LBPS7/2.
8. Recommendation on integrase inhibitor use in antiretroviral treatment-naive HIV infected individuals from the hhs panel on antiretroviral guidelines for adults and adolescents Panel on Antiretroviral Guidelines for Adults and Adolescents, (accessed March 25, 2014). http://aidsinfo.nih.gov/contentiles/upload/AdultARV_INSTIRecommendations.pdf.
9. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2014, 15(suppl 1):1-85.
10. Guidance for industry: E9 statistical principles for clinical trials US Food and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, Center for Biologic Evaluation and ResearchCenter for Biologic Evaluation and Research, (accessed April 29, 2014). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073137.pdf.
11. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements-clinical considerations for accelerated and traditional approval US Food and Drug Administration, Center for Drug Evaluation and ResearchCenter for Drug Evaluation and Research, (accessed March 25, 2014). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070968.pdf.
12. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inform J 2011, 45:291-300.
13. Chan IS, Zhang Z Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics 1999, 55:1202-1209.
14. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
15. Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS 2011, 25:1481-1487.
16. Fabbiani M, Mondi A, Colafigli M, et al. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). Scand J Infect Dis 2014, 46:34-45.
17. Arribas JR, Pialoux G, Gathe J, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis 2014, published online June 5. http://dx.doi.org/10.1016/S1473-3099(14)70782-0.
18. Nelson M, Winston A, Waters L, et al. Multicentre open-label study of switching from atripla to eviplera for possible efavirenz associated CNS toxicity. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapeutic; Denver, CO, USA; September 10-13, 2013. abstract H-672B.
19. Waters L, Fisher M, Winston A, et al. A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS 2011, 25:65-71.
20. German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr 2012, 61:32-40.
21. Stray KM, Bam RA, Birkus G, et al. Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir. Antimicrob Agents Chemother 2013, 57:4882-4889.
22. Post F, Villanueva JA, Fisher M, et al. Renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and cobicistat-boosted protease inhibitor regimens in HIV-1-infected patients with mild to moderate renal impairment. 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; Kuala Lumpur, Malaysia. June 30 to July 3, 2013. abstract TUPE280.
23. NORVIR (ritonavir) capsules, soft gelatin for oral use. US Prescribing Information AbbVie Inc, (accessed May 22, 2014). http://www.rxabbvie.com/pdf/norpi2a.pdf.
24. Hodder SL, Mounzer K, DeJesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010, 24:97. 96.
25. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010, 4:115-125.
26. Bangsberg DR, Ragland K, Monk A, Deeks SG A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010, 24:2835-2840.
27. Cohen CJ, Meyers JL, Davis KL Association between daily antiretroviral pill burden and treatment adherence, hospitalization risk, and other health utilisation and costs in a US medicaid population with HIV. BMJ Open 2013, 3:e003028.
28. Sax PE, Meyers JL, Mugavero M, Davis KL Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One 2012, 7:e31591.
29. Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquir Immune Defic Syndr 2014, 65:587-596.
30. Llibre JM, Arribas JR, Domingo P, et al. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011, 25:1683-1690.